Navigation Links
Newly Approved HIV Drug Shows Great Promise
Date:1/30/2008

Pricing Level Should Improve Access

WASHINGTON, Jan. 30 /PRNewswire/ -- The AIDS Institute, a national public policy research, advocacy, and education organization, is encouraged with the FDA's approval of the first new non-nucleoside reverse transcriptase inhibitor (NNRTI) in nearly a decade. TMC125/etravirine was developed by Tibotec Pharmaceuticals, Ltd. and will be marketed in the U.S. by Tibotec Therapeutics as Intelence(R), a division of Ortho Biotech Products, L.P. The company announced introductory pricing for the new NNRTI at $21.80 per day, which is substantially lower than other recently introduced antiretrovirals.

In a Title II Community AIDS National Network release dated January 19, 2008, Dr. Donna Christian-Chistensen, Chair of the Congressional Black Caucus Health Brain Trust stated: "The efficacy that Intelence (TMC125/etravirine) has shown in the DUET studies is impressive. Intelence is an important new HIV medication that, for the first time, re-opens the NNRTI class to patients with NNRTI-resistant virus. We applaud Tibotec for its efforts to make this innovative new medication available and accessible to people living with HIV."

The U.S. Food and Drug Administration (FDA) granted accelerated approval to the anti-HIV medication. This is the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to show antiviral activity in treatment- experienced adult patients with HIV resistant to an NNRTI and other antiretroviral (ARV) agents. Intelence, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment- experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to an NNRTI and other ARV agents. This indication is based on Week 24 analyses from two randomized, double-blind, placebo-controlled trials of Intelence. Both studies were conducted in clinically advanced
'/>"/>

SOURCE The AIDS Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
4. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
7. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
8. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
9. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... N.J. , March 2, 2015  Champions Oncology, ... of advanced technology solutions and services to personalize the ... 30 day extension on the $2 million convertible promissory ... December 1, 2014.  Dr. David ... "Champions continues to benefit from the confidence and commitment ...
(Date:3/2/2015)... VANCOUVER , Canada and HOUSTON, TX ... ("ESSA" or the "Company") (TSX-V: EPI) today reported financial ... December 31, 2014.  Amounts, unless specified otherwise, are expressed ... Reporting Standards (IFRS). Summary Results ... million ($0.10 per common share) for the three months ...
(Date:3/2/2015)... 2015 Attorney Advertising -- Bronstein, Gewirtz ... behalf of purchasers of the securities of Vitae ... VTAE -News).  Such investors are advised to contact ... coordinator Eitan Kimelman at info@bgandg.com ... whether Vitae Pharmaceuticals and certain of its officers ...
Breaking Medicine Technology:Champions Oncology Extends Convertible Debt Financing 2Champions Oncology Extends Convertible Debt Financing 3ESSA Pharma Inc. Reports First Quarter 2015 Financial Results 2ESSA Pharma Inc. Reports First Quarter 2015 Financial Results 3ESSA Pharma Inc. Reports First Quarter 2015 Financial Results 4SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vitae Pharmaceuticals, Inc. 2
... N.C., Jan. 26, 2011 MedCath Corporation (Nasdaq: ... closes on February 9, 2011 to announce results from its ... MedCath has elected not to host a conference call to ... Corporation, headquartered in Charlotte, N.C., is a healthcare provider focused ...
... 2011 Boston Scientific Corporation (NYSE: BSX ... the PLATINUM China clinical trial, which is designed to ... Element™ Everolimus-Eluting Platinum Chromium Coronary Stent compared to the ... patients with a single de novo atherosclerotic ...
Cached Medicine Technology:Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent 2Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent 3Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent 4
(Date:3/2/2015)... (PRWEB) March 02, 2015 Burns ... temperature calibration for Secondary Standard Platinum Resistance Thermometers ... 5 business days or less . . . ... NVLAP ® Accredited (Lab Code 200706-0), ISO 9001 ... Temperature range is -196°C to 500°C, both ...
(Date:3/2/2015)... Over the last five years the ultrasound market has ... their geographic presence and achieve economies of scale. The ... by 2019 at CAGR of 5.1% from 2014 to ... and a major part of Europe are mature markets ... including China and India, Latin America and the Middle ...
(Date:3/2/2015)... 2015 This year, the National Multiple Sclerosis ... provide opportunities for people across the country to unite, ... with MS live their best lives. MS Awareness Week is ... others to join the Society’s vision of a world free ... disabling disease of the central nervous system, interrupts the flow ...
(Date:3/2/2015)... Atlantic Information Services, Inc. (AIS) is ... of Health Plans: 2015 , the all-new 12th edition ... health plan market, with enrollment data and contact information ... , Available as a printed book containing the full ... quick-view tables and charts, as well as an electronic ...
(Date:3/2/2015)... A true renaissance man—some might call him ... cult rock band Khazad Doom, has long inspired his countless ... despite all odds. His motto throughout his life has always ... goal was before him. And that attitude, born amidst the ... on to a new generation. , As Eadon knows, when ...
Breaking Medicine News(10 mins):Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 3
... Association Intervention Tool Kit Reduces Patient ... Injuries/Repeat Visits and Risky Drinking, DES ... Alcohol Screening Day, 360 nurses in emergency departments,nationwide will ... intervention tool kit designed to address alcohol use,problems with ...
... Enhance Flexible Premium Universal ... Life ... many Americans seek financial guarantees. AXA Equitable Life,Insurance Company announced today ... by offering more competitive rates in,approved jurisdictions on its Athena Universal ...
... 2008 Principals announced today a $3,billion dollar ... with,chemical manufacturer W.R.Grace & Co. and related entities, ... from bankruptcy,with no further obligations for asbestos injury ... the 1970,s., Terms of the agreement will ...
... Stiefel Laboratories,Inc., the world,s largest independent pharmaceutical company ... has been,promoted to the newly created position of ... chief scientific officer will reinforce the,already critical role ... between,all R&D departments. It also will further strengthen ...
... mammals (and this naturally includes humans) is an extraordinarily complex ... also to the formation in healthy eyes of elastic and ... the ciliary muscles, the lens can change its degree of ... As a result, a pin sharp image is created on ...
... 2008 Quest Diagnostics,Incorporated (NYSE: DGX ), the ... today that it will make public,its first-quarter 2008 results ... it will conduct it,s first quarter investor conference call,at ... may access the conference call through a live audio ...
Cached Medicine News:Health News:Emergency Departments Nationwide Institute New Alcohol Screening and Intervention Process 2Health News:AXA Equitable Helps Americans Secure Their Financial Future with More Affordable Lapse Protection Coverage 2Health News:AXA Equitable Helps Americans Secure Their Financial Future with More Affordable Lapse Protection Coverage 3Health News:AXA Equitable Helps Americans Secure Their Financial Future with More Affordable Lapse Protection Coverage 4Health News:$3 Billion Asbestos Deal Reached by W.R.Grace Company to Pay Asbestos Victims 2Health News:Stiefel Laboratories Appoints First Chief Scientific Officer 2Health News:Stiefel Laboratories Appoints First Chief Scientific Officer 3Health News:When poor communication pokes you in the eye 2Health News:Quest Diagnostics to Release First Quarter 2008 Financial Results and Conduct Quarterly Investor Conference Call 2
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... Centuries of German Craftsmanship have ... in the world. Ocutek now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
... platform with integrated neck. Piston assembly ... an internal spring to recoil back ... Block fits into precision milled cavity ... sized 6.25 - 9.0mm. Designed for ...
... Central platform with integrated neck. ... platform utilizing an internal spring to ... use. Cutting Block fits into precision ... trephine blades sized 6.25 - 9.0mm. ...
Medicine Products: